Clinical Development


Our laboratory is a certified, independently operating analytical laboratory, providing advanced and sophisticated analytical services with experienced professionals and state-of-the-art instrumentation.

Analysis of active ingredients as such, in blends and finished products such as soft and hard gel caps, tablets and capsules.

Primary packaging - bottling of tablets and capsules.

ACE's up-to-date premises for the manufacturing of clinical trial medication.

Altrabio expertise
Bridge the gap between biologists, statisticians and informaticians.
Outliers and data quality issues
Detect outliers and quality issues that cloud your data.
Life science data analysis and interpretation
Find the needles in your haystack - AltraBio provides expertise in state-of-the-art and innovative life science data analysis and interpretation.
Biomedical knowledge
Place your results in the context of current biomedical knowledge.
New subgroups in your population
Identify new subgroups in your population.

Nucleic acid biomarkers
Array-based technology platforms incorporating novel protein and nucleic acid biomarkers are increasingly being adopted by mainstream diagnostic testing laboratories.
Automated testing platforms
Automated testing platforms are now available for even the most esoteric assays, enabling the adoption of those tests into routine testing laboratories.
Novel biomarkers as diagnostic tests
Biosensor technology is enabling the delivery of diagnostic tests based on novel biomarkers at the point of care.

Europa Bioproducts
Europa Bioproducts specialises in the distribution of enzymes, kits and reagents used in the characterisation and analysis of the glycosylation patterns of therapeutic proteins and monoclonal antibodies.
Post-translational modification
Post-translational modification is important to characterise and monitor because glycosylation has a significant impact on the efficacy, pharmokinetics and safety of the drug.
Oligosaccharide (glycan) profiling and sequencing
Our products allow companies to perform oligosaccharide (glycan) profiling, oligosaccharide (glycan) sequencing and monosaccharide composition.
Signal labelling kits
We have 2-AA (for monosaccharide composition), 2-AB (for oligosaccharide / glycan profiling) and DMB (for sialic acids) Signal labelling kits.
Preliminary identification
Preliminary identification can be achieved by calibrating the column with a 2-AB labelled dextran ladder and comparing retention times to known standards or databases.

FOCUS Clinical Drug Development
FOCUS Clinical Drug Development is an independent full-service CRO that specialises in exploratory clinical drug development and integrated proof of concept (PoC) packages.
FOCUS's Neuss Unit
FOCUS's Neuss Unit has performed >600 Ph I-III studies, more than 80 first-in-man studies (NCE / NBE) and 38 Ph I studies in Japanese subjects since 1997.
FOCUS headquarters
FOCUS headquarters in Neuss, Germany.
Development candidates
FOCUS can progress your development candidate from preclinical / discovery stage to clinical PoC in the most timely and economical fashion, via an integrated project management.
FOCUS Immunology
FOCUS Immunology offers a range of services for exploratory drug development.

Imaging peptides by introducing thioether bridges
LanthioPep increases the in vivo stability of therapeutic and diagnostic imaging peptides by introducing thioether bridges in these peptides.
LanthioPep’s thioether-bridge technology
LanthioPep’s thioether-bridge technology endows peptides with intrinsic in vivo stability thus creating new prospects for unstable peptide drug candidates.
Thioether bridges
LanthioPep has introduced thioether bridges into a broad range of peptides, including peptide hormones and diagnostic imaging peptides.
Stabilised peptide therapeutics and diagnostic imaging candidates
LanthioPep is developing its own stabilised peptide therapeutics and diagnostic imaging candidates.


Our fifth annual Pharmacovigilance and Risk Management conference will be held 1-2 December 2009 in Brussels, Belgium.
Pharma and biotech manufacturers
The conference will bring together major pharma and biotech manufacturers, as well as regulators, to discuss the important issues of pharmacovigilance and risk management.

This two-day conference will ensure you effectively manage risk management with current medicines to mitigate any risks to patients.


Newsletter Sign-Up
For all the latest news in the industry, sign up here

Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development